Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout

Table 3 Forward stepwise logistic regression analysis of factors associated with SU target in those taking ULT

Variable	Odds ratio	95% CI	p	Model
Female sex	4.3	1.6-11.4	0.003	Adjusted R² = 0.35, p < 0.001
Māori or Pacific ethnicity	0.19	0.07-0.52	0.001
Allopurinol dose (per every 100 mg/day)	2.22	1.43-3.44	<0.001
Confidence to keep serum urate under control (per every point on 0–10 Likert scale)	1.025	1.007-1.044	0.006

Excluded from model: secondary care treatment, adherence score, age, confidence to have blood tests at recommended frequency, confidence to take gout medications regularly, BIPQ treatment control score, BIPQ understanding score.
Model included all factors with p < 0.15 between groups in univariate analysis.

ISSN: 1471-2474